MedTrace Logo

SSRI and Buprenorphine

NCT00475878 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2012-04-03

Study results available
· View outcomes & findings →

Summary

This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Conditions

Interventions

DRUG

escitalopram

10mg escitalopram/day for 3 months

DRUG

placebo

placebo capsule/day for 3 months

Sponsors & Collaborators

  • Butler Hospital

    lead OTHER

Principal Investigators

  • Michael D Stein, M.D. · Rhode Island Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00475878 on ClinicalTrials.gov